Please login to the form below

ivabradine

This page shows the latest ivabradine news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.

Latest news

Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart
Shire and Baxalta drugs among CHMP's latest recommendations

ANPHARM Przedsiębiorstwo Farmaceutyczne's Ivabradine Anpharm (ivabradine) for the treatment of stable chronic angina pectoris and chronic heart failure.
Amgen starts shipping Corlaner in US

Corlaner (ivabradine) - the first new medicine for chronic heart failure in the US in almost a decade - will be available in pharmacies before the end of the week, according to
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). ... on ivabradine sales on the back of US approval and a
Amgen banking on three launches in 2015

year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma.

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

While Entresto has captured the headlines of late, there was another key development in HF therapy this year after Amgen secured approval in the US for Corlaner (ivabradine), a drug that ... Ivabradine is thought to be the first drug to work by
Deal Watch table for July 2013

100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... Over 40 European countries, Australia, New Zealand . ‡ North America. ‡‡ Amgen receives
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Healthcare PR Senior Account Manager: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer: Salary is DOE

Sudler London - Senior Medical Writer: Competitive

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Associate Scientific Director: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Sudler London - Account Director: Competitive

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Writer, Healthcare Advertising, London: Excellent package

Systematic Review Lead- London: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Market Access Consultant - Greater Manchester: Negotiable

Medical Writer - Creative and Scientific Projects: DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....